Agatolimod [PF-3512676] has potential as an adjuvant therapy in malignant melanoma

Author：  

Publisher： Adis International

ISSN： 1173-8324

Source： Inpharma, Vol.1, Iss.1653, 2008-01, pp. : 8-8

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

CpG 7909: PF 3512676, PF-3512676

By Adis International Limited  

Drugs in R&D, Vol. 7, Iss. 5, 2006-01 ,pp. : 312-316

Adis International

Access to resources Recommend Favorite

Cost-effectiveness of interferon-α2 as adjuvant therapy in malignant melanoma

By Lafuma Antoine   Grob Jean Jacques  

Expert Opinion on Pharmacotherapy, Vol. 4, Iss. 3, 2003-03 ,pp. : 343-349

Informa Healthcare

Access to resources Recommend Favorite

The combination of imexon and dacarbazine has shown potential in patients with advanced malignant melanoma

By  

Inpharma, Vol. 1, Iss. 1556, 2006-01 ,pp. : 8-8

Adis International

Access to resources Recommend Favorite

Sargramostim: potential adjuvant therapy in melanoma?

By  

Inpharma, Vol. 1, Iss. 1240, 2000-01 ,pp. : 17-17

Adis International

Access to resources Recommend Favorite

Adjuvant interferon- -2a of no benefit in malignant melanoma

By  

Inpharma, Vol. 1, Iss. 1306, 2001-01 ,pp. : 13-13

Adis International

Access to resources Recommend Favorite